YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma
YMN-V115 represents a next-generation trispecific T-cell engager that effectively addresses antigenic heterogeneity and immune evasion in MM. These preclinical findings support its further clinical development as a promising therapeutic strategy for relapsed or refractory MM.
Authors
- Qizhong Lu
- Huaqing Lu
- Aiping Tong (ORCID: https://orcid.org/0000-0002-3392-5443)
- Hai Xie (ORCID: https://orcid.org/0000-0002-3829-6842)
- Hexian Li (ORCID: https://orcid.org/0000-0002-0445-8014)
- Zhixiong Zhu
- Yongdong Chen
- Chunlai Nie
- Ting Niu
- Zhengyu Yu
- Nian Yang
- Zeng Wang
- Yangji Chen
- Zongliang Zhang
- Jia Li
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013986
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00